定量药理学与新药注册

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (10): 1081-1091.

• 专论 • 下一篇

定量药理学与新药注册

王亚宁

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, USA

发布日期:2020-09-16

Published:2020-09-16
About author:Dr. Wang is currently the Associate Director for Science in Division of Pharmacometrics in the Office of Clinical Pharmacology at FDA. Before joining FDA in 2003, Dr. Wang received his PhD in pharmaceutics and master degree in statistics from University of Florida during 1999 to 2003. He also obtained a master degree in Biochemistry (1999) from Peking University of Physical Education and a bachelor degree in Pharmacy (1996) from Beijing Medical University(Currently Peking University Health Science Center) in China. Dr. Wang's research interest involves application of quantitative methodology in clinical pharmacology to facilitate decision making in drug development and review. Dr. Wang also oversees the scientific aspects of critical path projects and policy development within Division of Pharmacometrics to ensure high quality science. Dr. Wang is a Courtesy Assistant Professor in the Department of Pharmaceutics at University of Florida and an invited lecturer in the College of Engineering and College of Pharmacy at University of Michigan. Dr. Wang received numerous awards at FDA, including FDA Award of Merit, the most prestigious honor award at FDA.

摘要/Abstract

王亚宁. 定量药理学与新药注册[J]. 中国临床药理学与治疗学, 2010, 15(10): 1081-1091.

[1] http://www.FDA.gov/AboutFDA/CentersOffices/CCER/ucm167032.htm.
[2] http://en.wikipeCia.org/wiki/Pharmacometrics.
[3] Wagner JG. History of pharmacokinetics[J]. Pharmacol Ther,1981, 12(3):537-562.
[4] HolforC NH, Sheiner LB. Kinetics of pharmacologic response[J]. Pharmacol Ther,1982, 16(2):143-166.
[5] Beal SL, Sheiner LB. Estimting population kinetics[J]. Crit Rev Biomed Eng, 1982,8(3):195-222.
[6] Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models[J]. Annu Rev Pharmacol Toxicol, 2009,49:291-301.
[7] Gobburu JV. Pharmacometrics 2020[J]. J Clin Pharmacol, 2010,50(9 Suppl):151S-157S.
[8] http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf.
[9] http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf.
[10] http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.
[11] Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approvals and labeling decisions: survey of 42 new drug applications[J]. AAPS J, 2005, 7(3):E503-512.
[12] Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric review on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006[J]. Clin Pharmacol Ther, 2007,81(2):213-221.
[13] Wang Y, Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA Pharmacometrics during 2004-2006[J]. J Clin Pharmacol, 2008, 48(2):146-156.
[14] Stone J, Banfield C, Pfister M, et al. Model-Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry[J]. J Clin Pharmacol,2010, 50(suppl 1):20S-30S.
[15] Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review[J]. J Clin Pharmacol, 2008, 48(1):13-18.
[16] http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/ucm082015.pdf.
[17] Stone J, Banfield C, Pfister M, et al. Model-Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry, J Chin Pharmacol, 2010,50(Suppl 1):20S-30S.
[18] Bhattaram VA, Siddiqui O, Kapcala L, et al. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease[J]. AAPS J, 2009,11(3):456-464.
[19] Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development[J]. Clin Pharmacol Ther, 2009, 86(2):167-174.
[20] http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm106189.htm.
[21] http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM215862.pdf.
[22] http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM188700.pdf.
[23] http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm.
[24] http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079748.pdf.
[25] http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079690.pdf.
[26] Russel T, Riley SP, Cook JA, et al. A perspective on the use of concentration-QT modelling in drug development[J]. J Clin Pharmacol, 2008, 48(1): 9-12.
[27] Tsong Y, Shen M, Zhong J, et al. Statistical issues of QT prolongation assessment based on linear concentration modeling[J]. J Biopharm Stat, 2008,18(3):564-584.
[28] Wang Y, Garnett C. Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al[J]. J Biopharm Stat, 2010, 20(3):689-692.
[29] Stanski DR, Orloff JJ. Communicating with the FDA: the "third rail" of a new model for drug development[J]. J Clin Pharmacol, 2008, 48: 144-145.
[30] Woosley RL. They are from the government and they really are here to help you[J]. J Clin Pharmacol, 2008, 48(2): 142-143.
[31] http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
[32] Funk GA, Fischer M, Joos B, et al. Quantification of in vivo replicative capacity of HIV-1 in different, compartments of infected cells[J]. J Acquir Immune Defica Syndr, 2001,26:397-404.
[33] Paterson D, Swindells S, Mohr J, et al. How Much Adherence is Enough? A Perspective Study of Adherence to Protease Inhibitor Therapy Using MEMSCaps, Abstract, 6th Conference on Retroviruses and Opportunistic Infections, 1999.
[34] http://www.aapspharmaceutica.com/meetings/annualmeet/am07/ProgramInfo/Prelim/program/ppdm_open.asp.
[35] http://www.nature.com/clpt/journal/v82/n1/extref/6100234x1.ppt.
[36] http://www.biopharmnet.com/doc/ACCP_TQT_2007.pdf.

定量药理学与新药注册

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价